Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice
Purpose We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A 4 via cyclooxygenase-2. Aspirin alone...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 2017-12, Vol.31 (5-6), p.489-500 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 500 |
|---|---|
| container_issue | 5-6 |
| container_start_page | 489 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 31 |
| creator | Ye, Yumei Nylander, Sven Birnbaum, Yochai |
| description | Purpose
We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A
4
via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A
4
, but when combined with statins, cyclooxygenase-2 is completely blocked.
Methods
ApoE
−/−
/db
+
/db
+
double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks. Serum 15-epi-lipoxin A
4
levels and aortic wall cholesterol content, IL-1β, IL-6, and TNF-α levels, and plaque area were assessed.
Results
Aspirin, ticagrelor, and rosuvastatin increased 15-epi-lipoxin A
4
levels. The combination of rosuvastatin + ticagrelor provided an additive effect. Aspirin attenuated the effect of both ticagrelor and rosuvastatin. Aspirin, ticagrelor, and rosuvastatin reduced the area of the atherosclerotic plaque. The combination of ticagrelor + rosuvastatin provided additive effects. There was a negative interaction when aspirin was combined with ticagrelor or rosuvastatin. Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1β and IL-6 levels. There was no interaction between aspirin and ticagrelor or aspirin and rosuvastatin, whereas combining rosuvastatin and ticagrelor provided an additive effect. Aspirin, ticagrelor, and rosuvastatin all decreased TNF-α levels. Aspirin attenuated the effect of both ticagrelor and rosuvastatin, and there was no additive effect of combining ticagrelor + rosuvastatin.
Conclusions
We found an intricate interaction between aspirin, ticagrelor, and rosuvastatin, as aspirin reduced both ticagrelor and rosuvastatin ability to ameliorate inflammation and atherosclerosis. In contrast, we found additive effects when ticagrelor and rosuvastatin were combined. |
| doi_str_mv | 10.1007/s10557-017-6763-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1970272083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1969425705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-fe5a2d3cbb268d7e572c65e6c2ed0cb9bea48ccf06f8f4a7719769f5aff41a873</originalsourceid><addsrcrecordid>eNp1kV1rHCEUhqU0NNu0P6A3ZaA3vcik6ow6XoakHwspLSW5ljPOcWuY0a3OBPob-qfr7iYlBHqjoM_zHuUl5A2jZ4xS9SEzKoSqKVO1VLKp9TOyYkI1teIte05WVHNaN5zKY_Iy51taHK27F-SYa9YJRpsV-XMTEtzh6MOmmn9itQ4zJrCzj6GKrjrPW598OK2uvYVNwjGm0wrCUP2IebmDPMPsCxj27vcUC5Lzg1vOUsx23K0-77V1cCNME-zzi3npocfZ2-qrt_iKHDkYM76-30_IzaeP1xdf6qtvn9cX51e1bZturh0K4ENj-57LblAoFLdSoLQcB2p73SO0nbWOSte5FpRiWkntBDjXMuhUc0LeH3K3Kf5aMM9m8tniOELAuGRTeMoVp11T0HdP0Nu4pFBeVyipWy4UFYViB8qWn-aEzmyTnyD9NoyaXVPm0JQpTZldU0YX5-198tJPOPwzHqopAD8AuVyFDaZHo_-b-hc3iaDI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1969425705</pqid></control><display><type>article</type><title>Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ye, Yumei ; Nylander, Sven ; Birnbaum, Yochai</creator><creatorcontrib>Ye, Yumei ; Nylander, Sven ; Birnbaum, Yochai</creatorcontrib><description>Purpose
We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A
4
via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A
4
, but when combined with statins, cyclooxygenase-2 is completely blocked.
Methods
ApoE
−/−
/db
+
/db
+
double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks. Serum 15-epi-lipoxin A
4
levels and aortic wall cholesterol content, IL-1β, IL-6, and TNF-α levels, and plaque area were assessed.
Results
Aspirin, ticagrelor, and rosuvastatin increased 15-epi-lipoxin A
4
levels. The combination of rosuvastatin + ticagrelor provided an additive effect. Aspirin attenuated the effect of both ticagrelor and rosuvastatin. Aspirin, ticagrelor, and rosuvastatin reduced the area of the atherosclerotic plaque. The combination of ticagrelor + rosuvastatin provided additive effects. There was a negative interaction when aspirin was combined with ticagrelor or rosuvastatin. Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1β and IL-6 levels. There was no interaction between aspirin and ticagrelor or aspirin and rosuvastatin, whereas combining rosuvastatin and ticagrelor provided an additive effect. Aspirin, ticagrelor, and rosuvastatin all decreased TNF-α levels. Aspirin attenuated the effect of both ticagrelor and rosuvastatin, and there was no additive effect of combining ticagrelor + rosuvastatin.
Conclusions
We found an intricate interaction between aspirin, ticagrelor, and rosuvastatin, as aspirin reduced both ticagrelor and rosuvastatin ability to ameliorate inflammation and atherosclerosis. In contrast, we found additive effects when ticagrelor and rosuvastatin were combined.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-017-6763-9</identifier><identifier>PMID: 29185103</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject><![CDATA[Adenosine - administration & dosage ; Adenosine - analogs & derivatives ; Adenosine - therapeutic use ; Animals ; Aorta ; Apolipoprotein E ; Apolipoproteins E - genetics ; Arteriosclerosis ; Aspirin ; Aspirin - administration & dosage ; Aspirin - therapeutic use ; Atherosclerosis ; Atherosclerosis - immunology ; Atherosclerosis - prevention & control ; Cardiology ; Cholesterol ; Clopidogrel ; Cyclooxygenase-2 ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - immunology ; Disease Progression ; Drug Interactions ; Inflammasomes ; Interleukin 6 ; Lipoxin A4 ; Medicine ; Medicine & Public Health ; Mice ; Mice, Knockout ; Original Article ; Rodents ; Rosuvastatin Calcium - administration & dosage ; Rosuvastatin Calcium - therapeutic use ; Statins ; Tumor necrosis factor-α]]></subject><ispartof>Cardiovascular drugs and therapy, 2017-12, Vol.31 (5-6), p.489-500</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2017</rights><rights>Cardiovascular Drugs and Therapy is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-fe5a2d3cbb268d7e572c65e6c2ed0cb9bea48ccf06f8f4a7719769f5aff41a873</citedby><cites>FETCH-LOGICAL-c438t-fe5a2d3cbb268d7e572c65e6c2ed0cb9bea48ccf06f8f4a7719769f5aff41a873</cites><orcidid>0000-0001-7653-6328</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10557-017-6763-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10557-017-6763-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29185103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Yumei</creatorcontrib><creatorcontrib>Nylander, Sven</creatorcontrib><creatorcontrib>Birnbaum, Yochai</creatorcontrib><title>Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Purpose
We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A
4
via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A
4
, but when combined with statins, cyclooxygenase-2 is completely blocked.
Methods
ApoE
−/−
/db
+
/db
+
double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks. Serum 15-epi-lipoxin A
4
levels and aortic wall cholesterol content, IL-1β, IL-6, and TNF-α levels, and plaque area were assessed.
Results
Aspirin, ticagrelor, and rosuvastatin increased 15-epi-lipoxin A
4
levels. The combination of rosuvastatin + ticagrelor provided an additive effect. Aspirin attenuated the effect of both ticagrelor and rosuvastatin. Aspirin, ticagrelor, and rosuvastatin reduced the area of the atherosclerotic plaque. The combination of ticagrelor + rosuvastatin provided additive effects. There was a negative interaction when aspirin was combined with ticagrelor or rosuvastatin. Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1β and IL-6 levels. There was no interaction between aspirin and ticagrelor or aspirin and rosuvastatin, whereas combining rosuvastatin and ticagrelor provided an additive effect. Aspirin, ticagrelor, and rosuvastatin all decreased TNF-α levels. Aspirin attenuated the effect of both ticagrelor and rosuvastatin, and there was no additive effect of combining ticagrelor + rosuvastatin.
Conclusions
We found an intricate interaction between aspirin, ticagrelor, and rosuvastatin, as aspirin reduced both ticagrelor and rosuvastatin ability to ameliorate inflammation and atherosclerosis. In contrast, we found additive effects when ticagrelor and rosuvastatin were combined.</description><subject>Adenosine - administration & dosage</subject><subject>Adenosine - analogs & derivatives</subject><subject>Adenosine - therapeutic use</subject><subject>Animals</subject><subject>Aorta</subject><subject>Apolipoprotein E</subject><subject>Apolipoproteins E - genetics</subject><subject>Arteriosclerosis</subject><subject>Aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - therapeutic use</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - immunology</subject><subject>Atherosclerosis - prevention & control</subject><subject>Cardiology</subject><subject>Cholesterol</subject><subject>Clopidogrel</subject><subject>Cyclooxygenase-2</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - immunology</subject><subject>Disease Progression</subject><subject>Drug Interactions</subject><subject>Inflammasomes</subject><subject>Interleukin 6</subject><subject>Lipoxin A4</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Original Article</subject><subject>Rodents</subject><subject>Rosuvastatin Calcium - administration & dosage</subject><subject>Rosuvastatin Calcium - therapeutic use</subject><subject>Statins</subject><subject>Tumor necrosis factor-α</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV1rHCEUhqU0NNu0P6A3ZaA3vcik6ow6XoakHwspLSW5ljPOcWuY0a3OBPob-qfr7iYlBHqjoM_zHuUl5A2jZ4xS9SEzKoSqKVO1VLKp9TOyYkI1teIte05WVHNaN5zKY_Iy51taHK27F-SYa9YJRpsV-XMTEtzh6MOmmn9itQ4zJrCzj6GKrjrPW598OK2uvYVNwjGm0wrCUP2IebmDPMPsCxj27vcUC5Lzg1vOUsx23K0-77V1cCNME-zzi3npocfZ2-qrt_iKHDkYM76-30_IzaeP1xdf6qtvn9cX51e1bZturh0K4ENj-57LblAoFLdSoLQcB2p73SO0nbWOSte5FpRiWkntBDjXMuhUc0LeH3K3Kf5aMM9m8tniOELAuGRTeMoVp11T0HdP0Nu4pFBeVyipWy4UFYViB8qWn-aEzmyTnyD9NoyaXVPm0JQpTZldU0YX5-198tJPOPwzHqopAD8AuVyFDaZHo_-b-hc3iaDI</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Ye, Yumei</creator><creator>Nylander, Sven</creator><creator>Birnbaum, Yochai</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7653-6328</orcidid></search><sort><creationdate>20171201</creationdate><title>Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice</title><author>Ye, Yumei ; Nylander, Sven ; Birnbaum, Yochai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-fe5a2d3cbb268d7e572c65e6c2ed0cb9bea48ccf06f8f4a7719769f5aff41a873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenosine - administration & dosage</topic><topic>Adenosine - analogs & derivatives</topic><topic>Adenosine - therapeutic use</topic><topic>Animals</topic><topic>Aorta</topic><topic>Apolipoprotein E</topic><topic>Apolipoproteins E - genetics</topic><topic>Arteriosclerosis</topic><topic>Aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - therapeutic use</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - immunology</topic><topic>Atherosclerosis - prevention & control</topic><topic>Cardiology</topic><topic>Cholesterol</topic><topic>Clopidogrel</topic><topic>Cyclooxygenase-2</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - immunology</topic><topic>Disease Progression</topic><topic>Drug Interactions</topic><topic>Inflammasomes</topic><topic>Interleukin 6</topic><topic>Lipoxin A4</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Original Article</topic><topic>Rodents</topic><topic>Rosuvastatin Calcium - administration & dosage</topic><topic>Rosuvastatin Calcium - therapeutic use</topic><topic>Statins</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Yumei</creatorcontrib><creatorcontrib>Nylander, Sven</creatorcontrib><creatorcontrib>Birnbaum, Yochai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Yumei</au><au>Nylander, Sven</au><au>Birnbaum, Yochai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>31</volume><issue>5-6</issue><spage>489</spage><epage>500</epage><pages>489-500</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><abstract>Purpose
We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A
4
via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A
4
, but when combined with statins, cyclooxygenase-2 is completely blocked.
Methods
ApoE
−/−
/db
+
/db
+
double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks. Serum 15-epi-lipoxin A
4
levels and aortic wall cholesterol content, IL-1β, IL-6, and TNF-α levels, and plaque area were assessed.
Results
Aspirin, ticagrelor, and rosuvastatin increased 15-epi-lipoxin A
4
levels. The combination of rosuvastatin + ticagrelor provided an additive effect. Aspirin attenuated the effect of both ticagrelor and rosuvastatin. Aspirin, ticagrelor, and rosuvastatin reduced the area of the atherosclerotic plaque. The combination of ticagrelor + rosuvastatin provided additive effects. There was a negative interaction when aspirin was combined with ticagrelor or rosuvastatin. Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1β and IL-6 levels. There was no interaction between aspirin and ticagrelor or aspirin and rosuvastatin, whereas combining rosuvastatin and ticagrelor provided an additive effect. Aspirin, ticagrelor, and rosuvastatin all decreased TNF-α levels. Aspirin attenuated the effect of both ticagrelor and rosuvastatin, and there was no additive effect of combining ticagrelor + rosuvastatin.
Conclusions
We found an intricate interaction between aspirin, ticagrelor, and rosuvastatin, as aspirin reduced both ticagrelor and rosuvastatin ability to ameliorate inflammation and atherosclerosis. In contrast, we found additive effects when ticagrelor and rosuvastatin were combined.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29185103</pmid><doi>10.1007/s10557-017-6763-9</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-7653-6328</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2017-12, Vol.31 (5-6), p.489-500 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1970272083 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenosine - administration & dosage Adenosine - analogs & derivatives Adenosine - therapeutic use Animals Aorta Apolipoprotein E Apolipoproteins E - genetics Arteriosclerosis Aspirin Aspirin - administration & dosage Aspirin - therapeutic use Atherosclerosis Atherosclerosis - immunology Atherosclerosis - prevention & control Cardiology Cholesterol Clopidogrel Cyclooxygenase-2 Diabetes Diabetes mellitus Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - immunology Disease Progression Drug Interactions Inflammasomes Interleukin 6 Lipoxin A4 Medicine Medicine & Public Health Mice Mice, Knockout Original Article Rodents Rosuvastatin Calcium - administration & dosage Rosuvastatin Calcium - therapeutic use Statins Tumor necrosis factor-α |
| title | Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A28%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unraveling%20the%20Interaction%20of%20Aspirin,%20Ticagrelor,%20and%20Rosuvastatin%20on%20the%20Progression%20of%20Atherosclerosis%20and%20Inflammation%20in%20Diabetic%20Mice&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Ye,%20Yumei&rft.date=2017-12-01&rft.volume=31&rft.issue=5-6&rft.spage=489&rft.epage=500&rft.pages=489-500&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/s10557-017-6763-9&rft_dat=%3Cproquest_cross%3E1969425705%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1969425705&rft_id=info:pmid/29185103&rfr_iscdi=true |